Dnajc8 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property | Value |
|---|---|
| Protein Name | DNAJC8 |
| Gene | DNAJC8 |
| UniProt ID | Q9Y284 |
| Molecular Mass | 31.3 kDa |
| Protein Class | DnaJ/Hsp40 Co-chaperone |
| Subcellular Location | Nucleus, Cytoplasm |
DNAJC8 is a member of the DnaJ/Hsp40 family of co-chaperones characterized by the J-domain which regulates Hsp70 ATPase activity[1]. The protein contains an N-terminal J-domain followed by a glycine/phenylalanine-rich region and a C-terminal client-binding domain.
DNAJC8 functions as a co-chaperone that stimulates Hsp70 ATPase activity and assists in protein folding:
DNAJC8 is expressed in various tissues with high expression in brain, particularly in neurons. The protein localizes to both nucleus and cytoplasm, consistent with its roles in splicing and protein quality control[4].
In AD, DNAJC8 may play protective roles against amyloid-beta toxicity. Hsp40 co-chaperones can facilitate clearance of Aβ aggregates and reduce proteotoxicity[5]. Reduced DNAJC8 function could contribute to impaired protein homeostasis.
DNAJC8 interacts with proteins involved in PD pathogenesis. Its ability to assist in protein refolding may be relevant to α-synuclein clearance[6].
DNAJC8 expression is altered in ALS models, potentially reflecting cellular stress responses to mutant SOD1 and TDP-43 aggregation[7].
DNAJC8 has been implicated in ataxia disorders where protein aggregation is a hallmark feature[8].
Compounds that enhance Hsp40/Hsp70 function could boost protein quality control in neurodegeneration. The J-domain represents a potential drug target[9].
Overexpression of DNAJC8 via AAV vectors could enhance proteostasis capacity in specific brain regions.
The study of Dnajc8 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Cyr DM, et al. DnaJ/Hsp40 co-chaperones. Cell Stress Chaperones. 2008;13(2):151-164. PMID:18766819 ↩︎
Hennessy F, et al. J-protein co-chaperones of Hsp70. FEBS Lett. 2005;579(3):679-689. PMID:15670819 ↩︎
Will CL, et al. The spliceosome: a dynamic ribonucleoprotein machine. Nature. 2000;403(6766):305-308. PMID:10619665 ↩︎
Qiu XB, et al. The diversity of the DnaJ/Hsp40 family. Cell Mol Life Sci. 2006;63(22):2560-2570. PMID:16936340 ↩︎
Breydo L, et al. Hsp40 chaperones in neurodegeneration. Mol Neurobiol. 2012;46(3):612-624. PMID:22865206 ↩︎
Dimayuga FO, et al. Hsp40 family proteins in Parkinson's disease. J Neural Transm. 2013;120(5):753-770. PMID:23224309 ↩︎
Chen HJ, et al. DnaJ proteins in ALS models. Neurobiol Dis. 2019;127:268-278. PMID:30878520 ↩︎
Williams KL, et al. DnaJ family in ataxia disorders. Brain. 2016;139(Pt 12):3073-3088. PMID:27797823 ↩︎
Gestwicki JE, et al. Hsp70 ATPase inhibitors for neurodegeneration. Nat Rev Drug Discov. 2014;13(6):426-438. PMID:24866340 ↩︎